Optometry experts prove the effectiveness of orthokeratology in myopic control

January 11, 2012 By Regina Yu in Diseases, Conditions, Syndromes

After a lengthy study spanning over four years, Professor Pauline Cho from the School of Optometry at The Hong Kong Polytechnic University (PolyU) and her research team concluded that orthokeratology not only can correct refractive error, but also effective in slowing the progression of myopia.

Myopia (or shortsightedness) is the most prevalent in Hong Kong population and especially for school children. Local Chinese students have a higher prevalence of regardless of whether they attend in local or international schools when compared with other ethnic groups. Myopia will bring inconvenience in everyday life and serious myopia is associated with , peripheral retinal breaks and glaucoma which may lead to permanent vision loss and blindness.

Orthokeratology is a non-surgical means of vision correction which must be administered by registered optometrists. Myopia is a refractive defect of the eye in which collimated light produces image focus in front of the retina. The longer the eyeball length, the higher degree of myopia. Patients who wish to receive ortholeratology must have a thorough eye examination to see if he or she is suitable for the treatment. Optometrist will dispense a pair of specially designed rigid contact lens made from high oxygen permeable material for wearing during . The lens will modify the corneal shape as well as to correct the focus of the eye in order to correct the wearer's vision. If successful, wearer can have clear vision without using any vision aids for the rest of the day.

In 1997, PolyU's School of Optometry established The Centre for Myopia Research to conduct clinical, genomic and proteomic research using a multi-disciplinary approach, pulling in expertise from all areas of clinical and basic science. Professor Pauline Cho is a pioneer in research on myopic control and has published her findings in Current Eye Research Journal in 2005. She and her team found evidence that orthokeratology may have a potential for controlling the progression of myopia in children, apart from vision correction. To further confirm the potential of orthokeratology, Professor Cho and her team commenced two clinical trials named ROMIO (Retardation Of Myopia In Orthokeratology) and TO-SEE (Toric Orthokeratology-Slowing Eyeball Elongation) in 2008.

The ROMIO study is the first randomized, single masked study in the world to investigate the effectiveness of orthokeratology for myopic control in children. Participants were 77 children aged 7 to 10 years old with myopia not more than 4.00D and were randomly assigned to orthokeratology or spectacle group. At the end of 24 months of the research, the increase in eyeball length in the orthokeratology group is 0.36mm and in whereas that of the spectacle group which is 0.63mm. The results prove that the increase of eyeball length in children wearing orthokeratology lenses was about 43% slower than those wearing spectacles.

In the TO-SEE study, 37 children aged 6 to 12 years old were recruited and to study the potential of orthokeratology in reduction of astigmatism. Myopia of the participants was not more than 4.50D and astigmatism between 1.25D and 3.50D. Professor Cho and her team found that toric design orthokeratology effectively reduced the astigmatism by 79% after one month of lens wear. At the end of 24 months, the eyeball length of the participants was 0.31mm which also showed significance proof on myopic control.

Professor Cho says due to advancement in science and technology, the design and materials of orthokeratology lens were greatly improved. The high oxygen permeable lens with enhanced corneal reshaping potential brings convenience to wearers in daily life. If wearers strictly follow the instructions of the optometrist and have regular check-up, over 60% of their myopia could be reduced after one overnight lens wear and the rest over two to four weeks.

Orthokeratology is a reversible treatment and can be stopped anytime. With the clinically proved results in correction, myopic control and astigmatism reduction, it represents a safe and effective solution for people with myopia.

Provided by The Hong Kong Polytechnic University

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

FDA warns of infections tied to Tennessee pharmacy

(AP)—Government health officials are investigating several health problems reported with potentially contaminated medications made by a Tennessee specialty pharmacy.

Diseases, Conditions, Syndromes created May 24, 2013 | popularity not rated yet | comments 0

Comorbidities common with alopecia areata

(HealthDay)—Comorbid conditions often accompany alopecia areata, according to a study published online May 22 in JAMA Dermatology.

Diseases, Conditions, Syndromes created May 24, 2013 | popularity not rated yet | comments 0

Top-ranked golfer beats scoliosis

(HealthDay)—As a world-class golfer, Stacy Lewis' accomplishments are remarkable. But it was a physical challenge in her childhood that defined her ascent to the top of her sport.

Diseases, Conditions, Syndromes created May 24, 2013 | popularity not rated yet | comments 0

Saudi to send animal samples to US in coronavirus probe (Update)

Saudi Arabia said Friday it would send samples taken from animals possibly infected with a deadly SARS-like virus to the United States for testing in a bid to find the source of disease.

Diseases, Conditions, Syndromes created May 24, 2013 | popularity not rated yet | comments 0

WHO voices deep concern over spread of SARS-like virus

The World Health Organization voiced deep concern Thursday over the SARS-like virus that has killed 22 people in less than a year, saying it might potentially spread more widely between humans.

Diseases, Conditions, Syndromes created May 24, 2013 | popularity 5 / 5 (1) | comments 0


First drug to improve heart failure mortality in over a decade

Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...

Heart failure accelerates male 'menopause'

Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...

Seniors more likely to crash when driving with pet, study finds

(HealthDay)—Animals make great companions for senior citizens, but elderly people who always drive with a pet in the car are far more likely to crash than those who never drive with a pet, researchers have ...

New immune system discovered

(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.

Death highest in heart failure patients admitted in January, on Friday, and overnight

Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...

Feds fight morning-after pill age ruling in NY

(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...